Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Lenvatinib use appears to disrupt wound healing

15 Nov 2019

Lenvatinib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor for thyroid and renal malignancies, seems to play a role in wound healing complications based on temporality and biologic plausibility, suggests evidence from the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

This case series showed a wide range in the reported time to identification of delayed wound healing from tissue injury or surgery (4–58 days). The time on initial lenvatinib exposure relative to the tissue injury was also wide-ranging, and this could have impacted the development and detection of impaired healing, according to the investigators.

“Healthcare professionals should be aware of this safety risk to facilitate prompt recognition and risk mitigation,” they said.

To assess wound healing complications as a potential safety risk for patients treated with lenvatinib, the FAERS database for postmarketing reports of wound healing complications with lenvatinib was searched between 13 February 2015 (FDA approval date) and 15 February 2017.

Nine FAERS cases of lenvatinib-related wound healing complications that were previously not reported in the medical literature were identified. Of these, seven involved postoperative wound healing complications, such as impaired healing or wound dehiscence.

“The US FDA has approved several VEGFR tyrosine kinase inhibitors, including lenvatinib, for thyroid and renal malignancies,” the investigators said. “Inhibition of the VEGFR signaling pathway impairs angiogenesis and can disrupt wound healing.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.